title: Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
abstract: Deletions of the derivative chromosome 9 have recently been reported in chronic myeloid leukemia. These deletions are large, occur at the time of the Philadelphia (Ph) translocation, span the translocation breakpoint, and represent a powerful prognostic indicator. However, the molecular mechanisms responsible for the poor prognosis associated with deletions are obscure, and several possible models are investigated here. First, we demonstrate that all derivative chromosome 9 deletions detected by fluorescence in situ hybridization were associated with an absence of ABL-BCR expression. However, loss of ABL-BCR expression also occurred without an overt deletion, suggesting the existence of other mechanisms by which ABL-BCR transcription can be abolished. Furthermore, analysis of survival in 160 patients demonstrated that loss of ABL-BCR expression, in contrast to deletion status, was not an indicator of poor prognosis. Second, we addressed the possibility that concomitant small deletions of the Ph chromosome modulate BCR-ABL transcription. Real-time reverse-transcription polymerase chain reaction was used to demonstrate that derivative chromosome 9 deletions were not accompanied by altered levels of BCR-ABL transcripts. Third, deletions may represent a consequence of genetic instability within the target cell at the time of the Ph translocation, with the poor prognosis reflecting a predisposition to subsequent additional genetic alterations. However, patients with deletions do not exhibit an increased frequency of secondary cytogenetic changes following disease progression. Taken together, these data support a model in which deletions of the derivative chromosome 9 result in rapid disease progression as a result of the loss of one or more genes within the deleted region.
authors.affiliation: Department of Hematology, University of Cambridge, United Kingdom.
authors.forename: Brian J P
authors.initials: BJ
authors.lastname: Huntly
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Bench
authors.forename: Eric
authors.initials: E
authors.lastname: Delabesse
authors.forename: Alistair G
authors.initials: AG
authors.lastname: Reid
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Mike A
authors.initials: MA
authors.lastname: Scott
authors.forename: Lynda
authors.initials: L
authors.lastname: Campbell
authors.forename: Jennie
authors.initials: J
authors.lastname: Byrne
authors.forename: Eleanor
authors.initials: E
authors.lastname: Pinto
authors.forename: Andre
authors.initials: A
authors.lastname: Brizard
authors.forename: Deitger
authors.initials: D
authors.lastname: Niedermeiser
authors.forename: Elizabeth P
authors.initials: EP
authors.lastname: Nacheva
authors.forename: Francois
authors.initials: F
authors.lastname: Guilhot
authors.forename: Michael
authors.initials: M
authors.lastname: Deininger
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Green
mesh_terms: D000328:Adult; D001752:Blast Crisis / Q000235:genetics; D002872:Chromosome Deletion; D002899:Chromosomes, Human, Pair 9; D018450:Disease Progression; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D010677:Philadelphia Chromosome; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D016019:Survival Analysis
chemical_list: D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; C406060:abl-bcr fusion protein, human; D016044:Fusion Proteins, bcr-abl